Drug Database
PA

pantoprazole

✓ Approved

Nanodaru · ATP4A · Small Molecule

What is pantoprazole?

pantoprazole is a small molecule developed by Nanodaru. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

CompanyNanodaru
Drug ClassSmall Molecule
Molecular TargetATP4A
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Nanodaru

Mechanism of Action

Molecular Targets

pantoprazole acts on 1 molecular target:

ATP4AATPase H+/K+ transporting subunit alpha (ATP6A)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

pantoprazole is developed for 4 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Gastrointestinal disordersDuodenal ulcer✓ Approved
Gastrointestinal disordersGastric ulcer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Gastrinoma✓ Approved
Gastrointestinal disordersGastrooesophageal reflux disease✓ Approved

Related Research Articles

PubMedGut and liver2026-07-24

The Effect of Tegoprazan for Prevention of Iatrogenic Ulcer Bleeding after Endoscopic Submucosal Dissection: A Noninferiority Randomized Clinical Trial.

Kim Joon Sung JS, Kim Byung-Wook BW, Cho Kwang Bum KB, Jang Jae Young JY et al.

Proton pump inhibitors (PPIs) effectively reduce bleeding in patients after endoscopic submucosal dissection (ESD). Tegoprazan, a potassium-competitive acid blocker, provides stronger acid suppression than PPIs do; however, its efficacy in preventing post-ESD bleeding has rarely been studied. The aim of this study was to compare the effects of tegoprazan and pantoprazole on post-ESD bleeding. In this randomized, multicenter trial, patients undergoing ESD for gastric epithelial neoplasms were randomly assigned to two groups; each received tegoprazan (50 mg once daily for 28 days) or pantoprazole (40 mg intravenously for 48 hours and orally once daily for 26 days). Adverse events and serum gastrin levels were assessed as safety outcomes. The per-protocol set comprised 238 patients (117 tegoprazan, 121 pantoprazole). Noninferiority (within an 8.3% margin) in the post-ESD bleeding rates within 4 weeks was confirmed (risk difference, -6.30%; 95% confidence interval [CI], -14.67% to 2.07%; p=0.0003), with rates of 9.40% (11/117) and 15.70% (19/121) for the tegoprazan and pantoprazole groups, respectively. The bleeding rates within 24 hours were 5.98% (7/117) and 10.74% (13/121), respectively (risk difference, -4.76%; 95% CI, -11.75% to 2.23%). No significant differences were observed in adverse events or serum gastrin levels between the groups. Tegoprazan was non-inferior to pantoprazole in its effectiveness in preventing post-ESD bleeding, with comparable safety profiles. Notably, administering oral tegoprazan can potentially shorten the length of hospital stay and reduce medical costs, supporting its potential clinical value. Tegoprazan is expected to replace high-dose intravenous PPI therapy for patients after ESD (CRIS registration: KCT0006850).

PMID 42494366
Read full article →
PubMedClinical medicine insights. Case reports2026-07-23

Successful Management of Refractory Cannabinoid Hyperemesis Syndrome With Topical Capsaicin: A Case Report With Proposed Mechanism of Action and Literature Review.

Ilyas Muhammad M, Fernando Anushka A, Choriyev Abubakir A, Adi Mohammad M et al.

Cannabinoid hyperemesis syndrome (CHS) is a debilitating disorder of chronic, heavy cannabis users characterized by cyclic severe nausea, vomiting, and abdominal pain that is classically relieved by hot baths. Standard antiemetics often fail, and dysregulation of endocannabinoid signaling with involvement of heat-sensitive TRPV1 channels has been proposed. Topical capsaicin - a TRPV1 agonist - has been reported in small series and case reports to reproduce the hot-water effect and rapidly relieve symptoms. A 28-year-old man with daily high-potency cannabis use (∼2 g/day for 7 years) presented to the emergency department with 48 hours of intractable non-bilious vomiting (∼20 episodes/day), severe periumbilical cramping (8/10), and a history of similar episodic flares relieved by prolonged hot showers. Initial ED therapy (IV fluids, ondansetron, metoclopramide, pantoprazole) produced minimal benefit; labs showed hypokalemic, hypochloremic metabolic alkalosis and pre-renal azotemia, with otherwise unremarkable imaging and enzymes. After informed consent, ∼2 g of 0.1% topical capsaicin cream was applied across the abdomen. The patient experienced an acute burning sensation for ∼15-30 minutes; retching ceased within 10 minutes, pain fell to 2/10 by 30 minutes and resolved by 90 minutes, and he tolerated oral intake. Vital signs normalized and electrolytes/renal function returned to baseline at 48-hour follow-up. He was discharged with counseling on cannabis cessation and a capsaicin tube for prodromal use. Topical capsaicin produced rapid, durable symptom resolution in this case of refractory CHS with only transient local discomfort. The effect is plausibly mediated by TRPV1 activation followed by peripheral desensitization, recapitulating the therapeutic hot-water response. Given consistent positive signals from case reports, series, and small pilot data, topical capsaicin is a low-risk, accessible adjunct for refractory CHS, but larger controlled studies are needed to define optimal dosing, duration, and long-term outcomes.

PMID 42491286
Read full article →
PubMedPharmaceutical research2026-07-22

Integrating Clinical Evidence with PBPK Modeling to Assess PPI-Clopidogrel-CYP2C19 Interactions in Chinese ACS Patients.

Liu Ya-Xin YX, Kuang Yun Y, Ma Jun-Long JL, Liu Jin-Long JL et al.

The interaction between proton pump inhibitors (PPIs) and clopidogrel in acute coronary syndrome (ACS) patients is mediated by CYP2C19 genetic variants. This study quantitatively assessed their CYP2C19 genotype-dependent impact on clopidogrel pharmacokinetics and pharmacodynamics using clinical data and physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling. A total of 409 ACS patients from a prospective clinical study were genotyped for CYP2C19 (*1, 2, and 3 alleles) and evaluated for platelet reactivity index (PRI) following clopidogrel therapy, with or without concomitant pantoprazole or lansoprazole use. A PBPK model was developed in PK-Sim, incorporating CYP2C19-specific metabolic pathways, and linked with a pharmacodynamic model of P2Y12 receptor inhibition to simulate the effects of genotypes and PPIs on platelet inhibition. In extensive metabolizer individuals, PPI coadministration modestly increased platelet reactivity, while no significant change occurred in poor metabolizers. The PBPK simulations accurately predicted pharmacokinetic parameters, with over 90% of Cmax and AUC values within 0.5-twofold of clinical data. The integrated drug-drug-gene interaction-pharmacodynamic framework effectively captured the active metabolite's exposure and platelet inhibition dynamics. These results provide a quantitative understanding of the genotype- and PPI-dependent effects on clopidogrel's pharmacodynamics, offering a tool to personalize therapy in ACS patients.

PMID 42481856
Read full article →
PubMedThe American journal of tropical medicine and hygiene2026-07-17

Eyelid Verrucous Sporotrichosis Caused by Sporothrix Brasiliensis Mimicking Cutaneous Leishmaniasis and Complicated by Drug-Drug Interaction.

Rodrigues Felipe Tavares FT, Dos Santos Amanda Ribeiro AR, de Almeida Sandro Rogério SR, Albuquerque Renata Chaves RC et al.

Sporotrichosis caused by Sporothrix brasiliensis is endemic in Brazil and may present with atypical clinical features. We report a case of verrucous sporotrichosis of the eyelid mimicking cutaneous leishmaniasis in a 28-year-old woman without cat exposure or trauma. Initial diagnostic studies were inconclusive, and prolonged treatment with oral itraconazole failed. Subsequent fungal culture and polymerase chain reaction established the diagnosis. Medication review revealed concomitant pantoprazole use, likely impairing itraconazole absorption through pH-dependent bioavailability. Lesion resolution occurred after a 3-month course of oral terbinafine. This case highlights two critical considerations: sporotrichosis should remain in the differential diagnosis of chronic verrucous lesions in endemic regions, and careful evaluation of drug-drug interactions is essential to prevent antifungal treatment failure.

PMID 42462702
Read full article →
PubMedJournal of gastroenterology and hepatology2026-07-13

High-Dose Oral Omeprazole Versus Continuous Intravenous Pantoprazole in Patients With High-Risk Peptic Ulcer Bleeding: A Single-Blinded Multicenter RCT.

Sriyudthsak Kanteera K, Nalinthassanai Nutbordee N, Sriapiraksa Bunyos B, Rattanachaisit Pakkapon P et al.

The efficacy of high-dose oral omeprazole in peptic ulcer bleeding after successful therapeutic hemostatic endoscopy has not been well established. This study aimed to compare the efficacy of high-dose oral omeprazole versus continuous intravenous (IV) pantoprazole in rebleeding and percent time of gastric pH above 6. Eligible patients were randomized with 1:1 concealed allocation to 40-mg oral omeprazole twice daily or IV pantoprazole 8 mg/h for 72 h after index gastroscopy. Gastric pH was measured for 24 h during 48-72 h after starting the assigned medication. Rebleeding at 72 h and 30 days, as well as 24-h gastric pH, were assessed. A total of 124 patients were analyzed. Seventy-two-hour rebleeding occurred in 1.6% (1/61) of the oral omeprazole group and 4.8% (3/63) of the IV pantoprazole group requiring endoscopic hemostasis (risk difference [RD] -3.1%, 95% CI -11.6% to 4.6%). Rebleeding within 30 days also showed no difference between groups (3.3% vs. 4.8%, RD -1.5%, 95% CI -10.1% to 7.0%). Gastric pH monitoring was completed in 48% (29/61) of the oral group and 41% (26/63) of the IV group. The median percentage of gastric pH > 6 was 56.3% (IQR 28.0%-92.0%) in the oral group and 27.3% (IQR 4.4%-77.7%) in the IV group (p = 0.064). High-dose oral omeprazole may represent a feasible alternative to continuous IV pantoprazole in terms of preventing rebleeding at 72 h and 30 days and maintaining gastric pH > 6 among patients with peptic ulcer bleeding who underwent successful therapeutic hemostatic endoscopy. Registration number: NCT04394663.

PMID 42438169
Read full article →
PubMedArchiv der Pharmazie2026-07-13

Gastroprotective Activity of Myrtenol Derivatives Obtained by Biocatalytic Esterification and Photooxidation.

Viana Ana Flávia Seraine Custódio AFSC, Kutyła Mateusz M, de Barros Fernandes Hélio H, Acha Boris Timah BT et al.

Many naturally occurring substances exhibit anti-ulcer properties. One promising area of research is the identification of terpenoid compounds with enhanced therapeutic and gastroprotective properties. The present study aimed to synthesize new terpenoid derivatives of myrtenol via biotransformation using freeze-dried Cladosporium cladosporioides mycelium or via porphyrin-based biomimetic transformation, and to evaluate their gastroprotective activity in an ethanol-induced gastric lesion model. Five myrtenyl esters (acetate, butyrate, caprylate, pelargonate, and laurate) and two oxidative derivatives (myrtenal and myrtenal oxide) were obtained with a high degree of purity (> 94%, GC). The anti-ulcer preventive effects of the compounds were evaluated in mice at doses ranging from 6.25 to 25 mg per kg of body weight. The mice were treated orally prior to the induction of ethanol-induced gastric lesions. All compounds exerted a gastroprotective effect, reducing the lesion area (mm2) compared to the negative control group. Notably, the gastroprotective effects of myrtenyl caprylate, myrtenyl pelargonate, and myrtenyl laurate were equivalent to those promoted by the clinical medicine pantoprazole.

PMID 42438274
Read full article →

+2389 more articles available with a free account

Sign up free to view all articles →

Ask about pantoprazole